BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).
Ryan Bruce Corcoran
No relevant relationships to disclose
Gerald Steven Falchook
Research Funding - GlaxoSmithKline
Other Remuneration - GlaxoSmithKline
Jeffrey R. Infante
No relevant relationships to disclose
Omid Hamid
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Wells A. Messersmith
Consultant or Advisory Role - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Eunice Lee Kwak
Consultant or Advisory Role - Pfizer; Roche/Genentech (U)
Research Funding - GlaxoSmithKline
David P. Ryan
No relevant relationships to disclose
Razelle Kurzrock
Research Funding - GlaxoSmithKline
Adrienne A Brenner
No relevant relationships to disclose
Jennifer Luan
No relevant relationships to disclose
Peng Sun
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Alicia J Allred
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Shonda M Little
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kiran Patel
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Scott Kopetz
No relevant relationships to disclose
Alan Paul Venook
Research Funding - GlaxoSmithKline